Provided by Tiger Trade Technology Pte. Ltd.

Urogen Pharma Ltd.

21.14
-0.5300-2.45%
Post-market: 21.140.00000.00%16:32 EST
Volume:594.28K
Turnover:12.60M
Market Cap:989.54M
PE:-6.11
High:22.12
Open:21.68
Low:20.20
Close:21.67
52wk High:30.00
52wk Low:3.42
Shares:46.81M
Float Shares:37.03M
Volume Ratio:0.87
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4606
EPS(LYR):-2.9590
ROE:-1481.26%
ROA:-33.96%
PB:-8.57
PE(LYR):-7.14

Loading ...

Feb 03, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 19, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 06, 2025

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Nov 06, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 06, 2025

Major Issues Report

Form 8-K - Current report
Sep 09, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 09, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 27, 2025

Major Issues Report

Form 8-K - Current report
Aug 07, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 07, 2025

Major Issues Report

Form 8-K - Current report
Jul 29, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 29, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 03, 2025

Major Issues Report

Form 8-K - Current report
Jun 13, 2025

Major Issues Report

Form 8-K - Current report
Jun 10, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 12, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 12, 2025

Major Issues Report

Form 8-K - Current report
May 01, 2025

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Mar 10, 2025

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 10, 2025

Major Issues Report

Form 8-K - Current report